NCT00492752View on ClinicalTrials.gov

A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

PHASE3CompletedINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

March 31, 2007

Study Completion Date

July 31, 2009

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Sorafenib (Nexavar, BAY43-9006)

multikinase inhibitor; Sorafenib 400 mg (orally) twice daily

DRUG

Placebo

Matching placebo (orally) twice daily

Trial Locations (23)

251

Taipei

333

Taoyuan District

500

Changhua

736

Tainan City

10016

Taipei

100021

Beijing

100039

Beijing

116011

Dalian

116027

Dalian

200003

Shanghai

200032

Shanghai

210003

Nanjing

210009

Nanjing

230022

Hefei

310016

Hangzhou

400038

Chongqing

430030

Wuhan

510060

Guangzhou

510515

Guangzhou

Unknown

Tianjin

152-703

Seoul

702-701

Daegu

138-736

Seoul

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY